Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N H Russell

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Leukemia|November 1, 2016
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemiaN Khan, R K Hills, P Virgo, et al.
British Journal of Haematology|October 1, 1992
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trialA Khwaja, D C Linch, A H Goldstone, et al.
Bone Marrow Transplantation|February 23, 2016
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCTD M Burns, S Rana, E Martin, et al.
Bone Marrow Transplantation|October 28, 2014
Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantationB E Shaw, F Lee, S Krishnamurthy, et al.
Blood|June 22, 2001
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapyA C Rawstron, B Kennedy, P A Evans, et al.
Leukemia|September 15, 2016
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemiaA K Burnett, N H Russell, R K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot studyI G McQuaker, A P Haynes, S Anderson, et al.
Leukemia|December 11, 2012
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trialA K Burnett, R K Hills, D Grimwade, et al.
British Journal of Haematology|February 3, 2005
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiationH M Hunter, K Peggs, R Powles, et al.
Clinical Molecular Pathology|April 1, 1996
Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selectionR G Owen, A P Haynes, P A Evans, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Leukemia|November 1, 2016
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemiaN Khan, R K Hills, P Virgo, et al.
British Journal of Haematology|October 1, 1992
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trialA Khwaja, D C Linch, A H Goldstone, et al.
Bone Marrow Transplantation|February 23, 2016
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCTD M Burns, S Rana, E Martin, et al.
Bone Marrow Transplantation|October 28, 2014
Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantationB E Shaw, F Lee, S Krishnamurthy, et al.
Blood|June 22, 2001
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapyA C Rawstron, B Kennedy, P A Evans, et al.
Leukemia|September 15, 2016
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemiaA K Burnett, N H Russell, R K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot studyI G McQuaker, A P Haynes, S Anderson, et al.
Leukemia|December 11, 2012
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trialA K Burnett, R K Hills, D Grimwade, et al.
British Journal of Haematology|February 3, 2005
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiationH M Hunter, K Peggs, R Powles, et al.
Clinical Molecular Pathology|April 1, 1996
Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selectionR G Owen, A P Haynes, P A Evans, et al.
Pageof 16